Obliterative airway disease after heterotopic tracheal xenotransplantation: Pathogenesis and prevention using new immunosuppressive agents

Transplantation

Volumn 64, Issue 3, 1997, Pages 373-383

  Reichenspurner, Hermann ^a   Soni, Vipal ^a   Nitschke, Michael ^a   Berry, Gerald J ^a   Brazelton, Timothy R ^a   Shorthouse, Randi ^a   Huang, Xinfan ^a   Reitz, Bruce A ^a   Morris, Randall E ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; RAPAMYCIN;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHIOLITIS; CONTROLLED STUDY; DRUG EFFECT; HISTOPATHOLOGY; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY INFILTRATE; MALE; NONHUMAN; ORGAN TRANSPLANTATION; PATHOGENESIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RAT; SYRIAN HAMSTER; XENOGRAFT; XENOTRANSPLANTATION;

AIRWAY OBSTRUCTION; ANIMALS; BRONCHIOLITIS OBLITERANS; CRICETINAE; CYCLOSPORINE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; IMMUNOSUPPRESSIVE AGENTS; MALE; MESOCRICETUS; RATS; RATS, INBRED BN; RATS, INBRED LEW; TRACHEA; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, HETEROTOPIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030753009     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199708150-00001     Document Type: Article

References (29)

1. Hosenpud JD, Novick RJ, Breen TJ, Keck B, Daily P. The Registry of the International Society for Heart and Lung Transplantation: Twelfth Official Report - 1995. J Heart Lung Transplant 1995; 14(5): 805.
2. Reichenspurner H, Girgis R, Robbins RC, et al. Obliterative bronchiolitis after lung and heart-lung transplantation. Ann Thorac Surg 1995; 60: 1845.
3. Huang XH, Reichenspurner H, Shorthouse R, Morris RE. Heterotopic tracheal allograft transplantation: a new model to study the molecular events causing obliterative airway disease (OAD) in rats [Abstract]. J Heart Lung Transplant 1995; 14(Suppl): 49.
4. Kemp E, Dieperink H, Jensen J, et al. Newer immunosuppressive drugs in concordant xenografting: transplantation of hamster heart to rat. Xenotransplantation 1994; 1: 102.
5. Calne RY. Organ transplantation between widely disparate species. Transplant Proc 1970; 2(4): 550.
6. Leventhal JR, Sakiyalak P, Witson J, et al. The synergistic effect of combined antibody and complement depletion of discordant cardiac xenograft survival in nonhuman primates. Transplantation 1994; 57(6): 974.
7. Fukushima N, Bouchart F, Gundry SR, et al. The role of anti-pig antibody in pig-to-baboon cardiac xenotransplant rejection. Transplantation 1994; 57(6): 923.
8. Leventhal JR, Matas AJ, Sun LH, et al. The immunopathology of cardiac xenograft rejection in the guinea pig-to-rat model. Transplantation 1993; 56(1): 1.
9. Yuh D, Gandy KE, Morris RE, et al. Leflunomide prolongs pulmonary allograft and xenograft survival. J Heart Lung Transplant 1995; 14(6): 1136.
10. Scheringa M, Buchner B, Geerling RA, et al. Chronic rejection after concordant xenografting. Transplant Proc 1994; 26(3): 1346.
11. Allaire E, Guettier C, Bruneval P, Plissonier D, Michel JB. Cell-free arterial grafts: morphologic characteristics of aortic isografts, allografts, and xenografts in rats. J Vasc Surg 1994; 19(3): 446.
12. Xiao F, Shen J, Chong A, et al. Control and reversal of chronic xenograft rejection in hamster-to-rat cardiac transplantation. Transplant Proc 1996; 28(2): 691.
13. Girgis R, Iping T, Berry G, et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 1996; 15(12): 1200.
14. Hertz MI, Jessurun J, King MB, Savik SK, Murray JJ. Reproduction of the obliterative bronchiolitis lesion after heterotopic transplantation of mouse airways. Am J Pathol 1993; 142(6): 1945.
15. Shimizu T, Nettesheim P, Ramaekers FC, Randell SH. Expression of "cell-type-specific" markers during rat tracheal epithelial regeneration. Am J Respir Cell Mol Biol 1992; 7(1): 30.
16. Menger MD, Wolf B, Hobel R, Schorlemmer HU, Messmer K. Microvascular phenomena during pancreatic islet graft rejection. Langenbecks Arch Chir 1991; 376(4): 214.
17. Nielsen B, Steinbruchel DA, Lillevang ST, Kemp E. Evidence for a primarily humoral rejection mechanism in concordant xenogenic heart transplantation: a sequential immunohistological study in a hamster-to-rat model. APMIS 1993; 101(8): 587.
18. Reichenspurner H, Girgis R, Robbins R, et al. Stanford experience with obliterative bronchiolitis after lung and heart-lung transplantation. Ann Thorac Surg 1996; 62: 1467.
19. Morris RE, Huang XH, Shorthouse R, Berry GJ. Use of cyclosporine (CsA), mycophenolic acid (MPA), rapamycin (RPM), leflunomide (LFM), or desoxyspergualin (DSG) for prevention and treatment of obliterative airway disease in new animal models. J Heart Lung Transplant 1995; 14(Suppl): 65.
20. Hasan R, Van den Bogaerde JB, Wallwork J, White DJ. Evidence that long-term survival of concordant xenografts is achieved by inhibition of antispecies antibody production. Transplantation 1992; 54(3): 408.
21. Koskinen PK, Kallio EA, Krebs R, Lemström KB. A dose-dependent inhibitory effect of cyclosporine A on obliterative bronchiolitis of rat tracheal allografts. Am J Respir Crit Care Med 1997; 155: 303.
22. Lin Y, Sobis H, Vandeputte M, Waer M. Induction therapy of leflunomide and cyclosporine allows for long-term xenograft survival under cyclosporine alone. Transplant Proc 1994; 26(5): 3052.
23. Bartlett RR, Dimitrijevic M, Mattar T, et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 1991; 32(1-2): 10.
24. Cao WW, Kao PN, Chao AC, et al. Mechanism of the antiproliferative action of leflunomide. J Heart Lung Transplant 1995; 14(6): 1016.
25. Nair R, Cao W, Morris RE. Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine. Immunol Lett 1995; 47: 171.
26. Chen H, Xu D, Wu J, Daloze P. Prolongation of hamster to rat xenograft survival by rapamycin. Transplant Proc 1995; 24(2): 715.
27. Cao W, Mohacsi P, Shorthouse R, Pratt R, Morris RE. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis: inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 1995; 59(3): 390.
28. Morris RE, Huang X, Gregory CR, et al. Studies in experimental models of chronic rejection: use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis. Transplant Proc 1995; 27(3): 2068.
29. Morris RE. Mechanisms of action of new immunosuppressive drugs. Ther Drug Monit 1995; 17: 564.